Replies to post #45858 on GoodFellas Big Board Catalyst and Chart Plays

[xtremezz]

CUR getting some life into it

Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial

ROCKVILLE, Md., Oct. 4, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase I trial to test Neuralstem's human spinal cord stem cells, NSI-566, in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will update trial data at the American Neurological Association annual meeting on Monday, October 8th (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3311). Dr. Feldman's poster presentation, "Completion and Outcomes of Phase I Intraspinal Stem Cell Transplantation Trial for ALS," will be up from 11:30-6:30. Dr. Feldman will be discussing the data between 5:30-6:30. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Dr. Feldman is the President of the American Neurological Association, as well as Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. Dr. Feldman is an unpaid consultant to Neuralstem.